As shown by our analysis of 80 BRCA1 carriers, mean levels of the marker in the study populations were significantly lower than in the group of females with benign gynecological disorders (functional and nonneoplastic cysts, uterine myomas, and endometrial polyps) in the whole examined groups and premenopausal patients. This evidence concerns the gene BRCA1 and endometrial polyp.